Peter Banks

BioTek (United States), Newcastle University

Papers

3

Total Citations

30

H-Index

2

About

Peter Banks is a pioneering figure in the automation of cell-based assays for drug discovery, with a focus on enhancing the efficiency and reliability of ADME/Tox (absorption, distribution, metabolism, excretion, and toxicity) testing. His key research areas include high-throughput screening, permeability assays, and hepatocyte-based toxicity models. Banks made major contributions by developing automated, 96-well format systems for drug absorption assays using Caco-2 and MDCK-MDR1 cell lines, as detailed in his most-cited work (22 citations), which streamlined the evaluation of compound permeability and transport—a critical step in drug development. He also advanced toxicology by creating a triplexed hepatocyte assay (6 citations) that simultaneously measures cell viability and CYP1A/3A induction, providing a more comprehensive view of drug-drug interaction risks. Additionally, his work on genome-wide quantitative fitness analysis (QFA) in yeast (2 citations) demonstrates his versatility in applying automation to genetic studies. Banks’ innovations have significantly reduced manual labor and increased throughput in pharmaceutical research, making him a key figure in modernizing preclinical drug testing.

Research Focus

Key Achievements

2
H-Index
3
Papers
30
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Automation of Cell-Based Drug Absorption Assays in 96-Well Format Using Permeable Support Systems
22 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: BioTek (United States), Newcastle University

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago